Come learn about our upcoming collaboration system for labs and researchers in the field of adult stem cells - CLICK HERE
The Adult Stem Cell Research (ASCR) Network is an Internet-based project of The Cell Therapy Foundation designed to be a well-maintained and reliable source of information for the public regarding adult stem cell research, as well as to be a community of practice and collaboration among fellow researchers. ASCR publishes the latest scientific news in the adult stem cell arena, identifies the leading researchers in the field, and locates key clinical trials; as well as connects the global community of adult stem cell researchers with one another.
First Heart Failure Patients Successfully Implanted with Angioblast Systems' "Off-the-Shelf" Adult Stem Cells Multiple US medical centers activly enrolling patients into first Phase 2 trial of allogeneic stem cells for congestive heart failure
NEW YORK, Oct 12, 2008 (BUSINESS WIRE) -- Angioblast Systems Inc. today announced successful initial safety results following commencement of the world's first clinical trial to use allogeneic adult stem cells obtained from an unrelated, universal donor to treat patients with congestive heart failure.
The multi-center Phase 2 trial is examining the safety and effectiveness of three different doses of the company's proprietary allogeneic, "off-the-shelf," universal donor Mesenchymal Precursor Cells (MPCs) injected by catheter into damaged heart muscle of patients with congestive heart failure.
Safety data from the first seven patients enrolled in the trial by Angioblast at medical centers in Arizona, California, and Minnesota were presented today at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in Washington D.C. Dr. Nabil Dib, Director of Cardiovascular Research for Chandler Regional and Mercy Gilbert Medical Centers in Arizona, reported that no adverse events had occurred in any of the first seven patients following the catheter procedure.
Hematopoietic stem cells and mesenchymal stem cells are known to more or less find their way to injured tissue. This is one of the reasons why companies such as Osiris can get away with simply intravenously injecting their mesenchymal stem cells and still get potent results. What mediates natural attraction of stem cells to injured tissue? Well on the one hand, ischemia associated with injury results in production of agents such as SDF-1 and VEGF which act as chemokines. On the other hand, platelet released agents such as sphingosine 1 phosphate also have been demonstrated to call stem cells.
How could one increase the ability of stem cells to home to injured tissue? One approach is to implant on the injured tissue a source of chemokines so to enhance migration. This was previously performed in the form of a SDF-1-fibrin patch which had efficacy in an animal model of infarction.
Suzanne Somers, Renowned Author, Medical Advocate, and Official Spokesperson for NeoStem, Inc., Inspires the Audience on The Ellen Degeneres Show
NEW YORK, Oct 08, 2008 /PRNewswire-FirstCall via COMTEX/ -- Lively discussion of potential therapies using Adult Stem Cells drives awareness among viewers; NeoStem experiences never before seen interest in its services NeoStem, Inc. which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, today announced the launch of its adult stem cell public awareness program, a key element of which is Company spokesperson, Suzanne Somers, who talks about the latest medical technology in her New York Times Bestseller "Breakthrough" which includes a chapter dedicated to NeoStem and the benefits of adult stem cell collection and storage. The live filming of Ms. Somers' own stem cell collection at the California HealthSpan Institute in San Diego, a member of the NeoStem adult stem cell collection network aired last month on ABC's "Nightline."
Answer to Curing a Failing Heart May Exist in Body’s Own "Do-It-Yourself" Repair Kit.
Arizona Heart Institute Pioneers Research That May Offer New Hope to Heart Failure Patients.
PHOENIX, ARIZONA / OCTOBER 8, 2008 /PRNewswire/ — Nationally, over 3,000 people are waiting for a heart transplant – and a new lease on life. Sadly, only half of those will receive a transplant. Now, pioneering research at Arizona Heart Institute (AHI) is paving the way for how to treat congestive heart failure (CHF) patients.
Called MyoCell® Muscle Stem Cell Therapy, the unique transplant procedure actually uses skeletal muscle stem cells (myoblasts) from the patient’s own body that are injected into the heart. This may create new functioning heart muscle.
Arizona Heart Institute has extensive knowledge in this area, having already completed two myoblast transplantation research studies in patients suffering from congestive heart failure (CHF), the first in 2002 involving the direct injection of myoblast cells into the heart during open heart surgery, and in 2004, the nation’s first delivery of myoblast cells using a minimally invasive, catheter-based approach.
The Stem Cell Research Center (SCRC) is a center of excellence dedicated to the application of musculoskeletal research focused on the development of...
We focus our investigations on the different cell subsets contained in stroma fraction of adipose tissues, their respective roles in the biology and plasticity of...
The Cardiovascular Research Institute (CRI) is the largest division of the MedStar Research Institute and focuses most of its translational and clinical research...
Our mission is to advance the current understanding of the use of stem cells in the treatment of patients with cardiovascular disease. The primary goal...
